chemieunternehmen.com

Evotec AG today announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-biologics-announce-collaboration-on-cancer-immunotherapy-5107

Evotec AG announced today that it has entered into a collaboration with Probiodrug AG, a privately owned biopharmaceutical company focused on the development of innovative drugs for the treatment of major age related diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-biology-collaboration-with-probiodrug-5101

Evotec AG today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-receives-cir-french-research-tax-credit-accreditation-5099

Evotec AG and Haplogen GmbH have signed a collaboration agreement to discover and develop small molecules against viral infectious diseases. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-partners-with-haplogen-to-develop-drugs-for-infectious-diseases-5097

Evotec AG today reported financial results and corporate updates for the third quarter and first nine months of 2012 ending 30 September 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-8-revenue-growth-and-a-positive-operating-result-of-eur29-m-in-the-first-nine-months-of-2012-5095

Evotec AG today announced that CHDI Foundation, Inc., a privately-funded not-for-profit research organisation dedicated to developing therapies for Huntington’s disease, has extended its collaboration with Evotec until the end of 2015. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-extends-ongoing-collaboration-with-chdi-foundation-5089

Evotec AG announced today that Dr Werner Lanthaler, Chief Executive Officer of Evotec, was awarded the prize ‚Turnarounder of the Year 2012‘. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ceo-awarded-turnarounder-of-the-year-2012-5091